Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Gemcitabine + MK-8776|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Gemcitabine||Gemzar||Difluorodeoxycytidine Hydrochlorothiazide|LY-188011||Chemotherapy - Antimetabolite 11||Gemzar (gemcitabine) is converted in cells to difluorodeoxycytidine di- and triphosphate (dFdCDP, dFdCTP), which act to inhibit ribonucleoside reductase and as a deoxynucleotide analog respectively, resulting in DNA strand termination and apoptosis (NCI Drug Dictionary).|
|MK-8776||SCH900776||CHK1 Inhibitor 14||MK-8776 is a selective CHK1 inhibitor, which may enhance sensitivity of tumor cells to chemotherapeutic agents (PMID: 22203733, PMID: 23594139).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||Gemcitabine + MK-8776||Phase I||Actionable||In a Phase I trial, the combination treatment of MK-8776 and Gemzar (gemcitabine) in patients with advanced solid tumors resulted in antitumor efficacy, including 2 patients with a partial response and 13 patients experiencing stable disease (PMID: 25605849).||25605849|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|